CA2303482A1 - Chimeric transcriptional activators and compositions and uses related thereto - Google Patents

Chimeric transcriptional activators and compositions and uses related thereto Download PDF

Info

Publication number
CA2303482A1
CA2303482A1 CA002303482A CA2303482A CA2303482A1 CA 2303482 A1 CA2303482 A1 CA 2303482A1 CA 002303482 A CA002303482 A CA 002303482A CA 2303482 A CA2303482 A CA 2303482A CA 2303482 A1 CA2303482 A1 CA 2303482A1
Authority
CA
Canada
Prior art keywords
gene
nucleic acid
domain
transcription
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002303482A
Other languages
English (en)
French (fr)
Inventor
Sridaran Natesan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ariad Gene Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2303482A1 publication Critical patent/CA2303482A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Landscapes

  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002303482A 1997-08-27 1997-08-27 Chimeric transcriptional activators and compositions and uses related thereto Abandoned CA2303482A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/015219 WO1999010508A1 (en) 1997-08-27 1997-08-27 Chimeric transcriptional activators and compositions and uses related thereto

Publications (1)

Publication Number Publication Date
CA2303482A1 true CA2303482A1 (en) 1999-03-04

Family

ID=22261527

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002303482A Abandoned CA2303482A1 (en) 1997-08-27 1997-08-27 Chimeric transcriptional activators and compositions and uses related thereto

Country Status (6)

Country Link
EP (1) EP1003886A1 (de)
JP (1) JP2001514007A (de)
AU (1) AU752129B2 (de)
CA (1) CA2303482A1 (de)
IL (1) IL134643A0 (de)
WO (1) WO1999010508A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2375490A1 (en) * 1999-06-18 2000-12-28 Ariad Gene Therapeutics, Inc. Chimeric oca-b transcription factors
CA2398010A1 (en) 2000-01-24 2001-07-26 The Trustees Of Columbia University In The City Of New York An in vivo screen using chemical inducers of dimerization
WO2001062780A1 (en) * 2000-02-24 2001-08-30 The Salk Institute For Biological Studies Gene expression system based on chimeric receptors
AU2000256183A1 (en) * 2000-06-16 2002-01-02 Ariad Gene Therapeutics, Inc. Chimeric hsf transcription factors
MXPA03007492A (es) * 2001-02-20 2004-10-15 Rheogene Holdings Inc Receptores de retinoide x quimerico y su uso en un sistema de expresion de gen inducible basado en receptor de ecdisona novedoso.
EP1435779A4 (de) 2001-09-24 2005-06-01 Sangamo Biosciences Inc Modulation von stammzellen mittels zinkfingerproteinen
US7083918B2 (en) 2002-04-24 2006-08-01 The Trustees Of Columbia University In The City Of New York Bacterial small-molecule three-hybrid system
AU2004274957B2 (en) 2003-09-19 2009-02-05 Sangamo Therapeutics, Inc. Engineered zinc finger proteins for regulation of gene expression
WO2006033859A2 (en) 2004-09-16 2006-03-30 Sangamo Biosciences, Inc. Compositions and methods for protein production
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
CA2793633A1 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP2699688A1 (de) 2011-04-20 2014-02-26 The Trustees Of The University Of Pennsylvania Dosierpläne und zusammensetzungen zur aav-vermittelten passiven immunisierung von luftbürtigen krankheitserregern
WO2016200543A2 (en) 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
SG11201808426XA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
SG11201907611WA (en) 2017-02-28 2019-09-27 Univ Pennsylvania Influenza vaccines based on aav vectors
HRP20240257T1 (hr) 2017-02-28 2024-05-24 The Trustees Of The University Of Pennsylvania Adeno-povezani virusni (aav) clade f vektor i njegova uporaba
SG11202003479TA (en) 2017-10-18 2020-05-28 Regenxbio Inc Fully-human post-translationally modified antibody therapeutics
CA3079565A1 (en) 2017-10-18 2019-04-25 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
CN113966236A (zh) 2019-04-03 2022-01-21 再生生物股份有限公司 眼睛病状的基因疗法
TW202106708A (zh) 2019-04-24 2021-02-16 美商銳進科斯生物股份有限公司 全人類轉譯後修飾之抗體治療劑
JP2022545967A (ja) 2019-08-26 2022-11-01 リジェネックスバイオ インコーポレイテッド 完全ヒト翻訳後修飾抗ＶＥＧＦ Ｆａｂを用いる糖尿病性網膜症の処置
KR20220081365A (ko) 2019-10-07 2022-06-15 리젠엑스바이오 인크. 아데노-연관 바이러스 벡터 약제학적 조성물 및 방법
EP4214242A1 (de) 2020-09-15 2023-07-26 RegenxBio Inc. Vektorisierte antikörper für antivirale therapie
EP4213890A1 (de) 2020-09-15 2023-07-26 RegenxBio Inc. Vektorisierte lanadlumab und verabreichung davon
CA3197342A1 (en) 2020-10-07 2022-04-14 Regenxbio Inc. Gene therapy for ocular manifestations of cln2 disease
CN116528892A (zh) 2020-10-28 2023-08-01 再生生物股份有限公司 用于眼部适应症的载体化抗TNF-α抗体
WO2022094157A1 (en) 2020-10-28 2022-05-05 Regenxbio Inc. Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
WO2022094255A2 (en) 2020-10-29 2022-05-05 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof
AU2021369833A1 (en) 2020-10-29 2023-06-08 Regenxbio Inc. Vectorized tnf-alpha antagonists for ocular indications
TW202237850A (zh) 2020-12-01 2022-10-01 賓州大學委員會 具有組織特異性靶向基序的新穎構成物及含有其之組成物
CN112661820B (zh) * 2020-12-31 2021-12-14 中国科学院天津工业生物技术研究所 天山根瘤菌转录调控蛋白MsiR突变蛋白及其在刀豆氨酸生物传感器中的应用
AR125406A1 (es) 2021-04-23 2023-07-12 Univ Pennsylvania Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen
TW202325845A (zh) 2021-10-02 2023-07-01 賓州大學委員會 新穎aav衣殼及含其之組成物
WO2023147304A1 (en) 2022-01-25 2023-08-03 The Trustees Of The University Of Pennsylvania Aav capsids for improved heart transduction and detargeting of liver
WO2023201308A1 (en) 2022-04-14 2023-10-19 Regenxbio Inc. Gene therapy for treating an ocular disease
WO2023205610A2 (en) 2022-04-18 2023-10-26 Regenxbio Inc. Hybrid aav capsids
WO2023215806A2 (en) 2022-05-03 2023-11-09 Regenxbio Inc. Vectorized anti-complement antibodies and complement agents and administration thereof
WO2023215807A1 (en) 2022-05-03 2023-11-09 Regenxbio Inc. VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
WO2024022474A1 (zh) * 2022-07-29 2024-02-01 南京百斯杰生物工程有限公司 一种嵌合型转录激活因子及其应用
WO2024073669A1 (en) 2022-09-30 2024-04-04 Regenxbio Inc. Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0882128A1 (de) * 1996-02-23 1998-12-09 Ariad Pharmaceuticals, Inc. Auf zellen basierendes testverfahren
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor

Also Published As

Publication number Publication date
EP1003886A1 (de) 2000-05-31
AU4240297A (en) 1999-03-16
JP2001514007A (ja) 2001-09-11
AU752129B2 (en) 2002-09-05
IL134643A0 (en) 2001-04-30
WO1999010508A1 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
AU752129B2 (en) Chimeric transcriptional activators and compositions and uses related thereto
US6015709A (en) Transcriptional activators, and compositions and uses related thereto
US6117680A (en) Compositions and methods for regulation of transcription
JP3817739B2 (ja) キメラｄｎａ結合性タンパク質
US6479653B1 (en) Compositions and method for regulation of transcription
US6326166B1 (en) Chimeric DNA-binding proteins
US5919667A (en) Modular assembly retroviral vectors and uses thereof
US6306649B1 (en) Heterologous transcription factors
WO1996006110A1 (en) Composite dna-binding proteins and materials and methods relating thereto
WO1997011176A2 (en) Cyclin/cdk associated proteins, and uses related thereto
CA2346962A1 (en) Fk506-based regulation of biological events
WO2000078951A1 (en) Chimeric oca-b transcription factors
WO2001098507A1 (en) Chimeric hsf transcription factors
WO2001018036A2 (en) Methods and reagents for regulating gene expression
Liu Characterization of negative regulatory proteins involved in tissue specific MMTV expression
MXPA99003470A (en) Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use
Jo Epigenetic regulation of gene structure and function with a cell-permeable DNA site-specific recombinase
MXPA97006928A (es) Sistema de expresion condicional

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued